Lipton, Allan

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research

Bone health and treatmentsBone Metabolism and Diseases

Cited by 490

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology

Bone health and treatmentsBone health and osteoporosis research

Cited by 389

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer

Bone health and treatmentsBone Metabolism and Diseases

Cited by 383

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

Fury, M. G., Lipton, A., Smith, K. M., Winston, C. B., & Pfister, D. G. (2007) · Cancer Immunology, Immunotherapy

Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research

Cited by 87

A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption

Suarez, T., Fizazi, K., Rahim, Y., Wilson, J., Fan, M., Jun, S., & Lipton, A. (2006) · Journal of Clinical Oncology

Bone health and treatmentsBone health and osteoporosis research

Cited by 11